Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-005899-36-IT (EUCTR)	09/03/2022	26/11/2021	Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib	A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib - -	Multiple Sclerosis MedDRA version: 21.0;Level: PT;Classification code 10080700;Term: Relapsing multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aubagio Product Name: Teriflunomide Product Code: [L04AA31] INN or Proposed INN: Teriflunomide Product Name: remibrutinib Product Code: [LOU064C1] INN or Proposed INN: Remibrutinib Other descriptive name: LOU064C1 Product Name: colestiramina Product Code: [-] INN or Proposed INN: COLESTIRAMINA Product Name: Carbone vegetale polvere Product Code: [-] INN or Proposed INN: CARBONE VEGETALE	NOVARTIS PHARMA AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	800	Phase 3	United States;Serbia;Hong Kong;Slovakia;Spain;Guatemala;Chile;Russian Federation;Colombia;Italy;Switzerland;United Kingdom;India;Argentina;Malaysia;China
2	NCT04410965 (ClinicalTrials.gov)	May 20, 2020	28/5/2020	Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks	Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks	Multiple Sclerosis	Drug: TERIFLUNOMIDE	Sanofi	NULL	Completed	18 Years	55 Years	All	82	Phase 4	China
3	NCT04129736 (ClinicalTrials.gov)	October 10, 2019	15/10/2019	Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis	Determination of Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Treated With Teriflunomide 14 mg Daily.	Multiple Sclerosis, Pharmacokinetics	Drug: Teriflunomide 14 MG	Jan Lycke	NULL	Completed	18 Years	65 Years	All	12	Phase 4	Sweden
4	EUCTR2016-004414-10-SE (EUCTR)	23/02/2018	02/01/2018	Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.	Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.	Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aubagio INN or Proposed INN: TERIFLUNOMIDE	MS Centrum, Department of Neurology, Sshlgrenska University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Sweden
5	NCT03122652 (ClinicalTrials.gov)	September 25, 2017	12/4/2017	Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome	Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study	Multiple Sclerosis	Drug: Teriflunomide 14 MG Oral Tablet [Aubagio];Drug: Placebo Oral Tablet	Centre Hospitalier Universitaire de Nice	Genzyme, a Sanofi Company	Completed	18 Years	N/A	All	125	Phase 3	France;Switzerland;Turkey;Germany;Martinique;Sweden;United Kingdom
6	NCT02587195 (ClinicalTrials.gov)	December 18, 2015	22/9/2015	A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period	A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period	Multiple Sclerosis	Drug: Teriflunomide	Centre Hospitalier Universitaire de Nice	NULL	Unknown status	18 Years	55 Years	All	5	Phase 3	France

先頭へ